Akari Therapeutics, Plc (AKTX) DCF Valuation

Akari Therapeutics, Plc (AKTX) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Akari Therapeutics, Plc (AKTX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate Akari Therapeutics, Plc's financial prospects like an expert! This (AKTX) DCF Calculator provides pre-filled financial data and the complete flexibility to modify revenue growth, WACC, margins, and other critical assumptions to align with your predictions.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -24.7 -20.4 -17.2 -23.1 -16.8 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -24.8 -20.5 -17.2 -23.1 -16.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 5.7 14.1 9.4 13.2 3.8 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories -1.0 -.5 .0 -2.5 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.2 3.4 1.8 .9 1.7 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -21.8 -17.6 -17.4 -9.1 -16.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -19.5 -15.9 -19.5 -7.4 -18.6 -1.7 .0 .0 .0 .0
WACC, % 8.94 8.94 8.94 8.94 8.94 8.94 8.94 8.94 8.94 8.94
PV UFCF
SUM PV UFCF -1.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -4
Equity Value 2
Diluted Shares Outstanding, MM 5
Equity Value Per Share 0.47

What You Will Get

  • Real Akari Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Akari Therapeutics, Plc (AKTX).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Akari Therapeutics.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Akari’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Akari Therapeutics.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Akari Therapeutics, Plc (AKTX).

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Akari Therapeutics, Plc (AKTX).
  • WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
  • Customizable Forecast Assumptions: Easily adjust growth projections, capital expenditures, and discount rates relevant to Akari Therapeutics, Plc (AKTX).
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Akari Therapeutics, Plc (AKTX).
  • Interactive Dashboard and Charts: Visual representations provide a summary of essential valuation metrics for straightforward analysis.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Akari Therapeutics’ data.
  • Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Akari Therapeutics’ intrinsic value.
  • Step 5: Make informed investment decisions or create reports based on the outputs.

Why Choose This Calculator for Akari Therapeutics, Plc (AKTX)?

  • Accurate Data: Up-to-date Akari financials provide trustworthy valuation outcomes.
  • Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Built-in calculations save you from starting from the ground up.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Simple design and clear instructions ensure accessibility for all users.

Who Should Use This Product?

  • Individual Investors: Gain insights to make informed decisions regarding investments in Akari Therapeutics (AKTX).
  • Financial Analysts: Enhance analysis efficiency with comprehensive financial models tailored for Akari Therapeutics (AKTX).
  • Consultants: Provide clients with accurate and timely valuation assessments of Akari Therapeutics (AKTX).
  • Business Owners: Learn from the valuation strategies of biotech companies like Akari Therapeutics (AKTX) to inform your own business plans.
  • Finance Students: Explore real-world valuation methodologies using data from Akari Therapeutics (AKTX).

What the Template Contains

  • Historical Data: Includes Akari Therapeutics' past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Akari Therapeutics' intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Akari Therapeutics' financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.